About Leap Therapeutics, Inc. - Common Stock (LPTX)
Leap Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies to improve the lives of patients with cancer and other diseases. The company's research primarily centers on advancing novel antibody-based treatments and biologics that target specific pathways involved in tumor growth and immune response. By leveraging cutting-edge scientific advancements, Leap Therapeutics aims to bring new hope to patients through its clinical programs, which explore potential solutions for previously unmet medical needs. The company collaborates with academic institutions and industry partners to accelerate the development of its therapeutic candidates. Read More
Health In Tech Inc. (NASDAQ: HIT), OSR Holdings Inc. (NASDAQ: OSRH), Theratechnologies Inc. (NASDAQ: THTX), and Leap Therapeutics Inc. (NASDAQ: LPTX) continue to push boundaries in healthcare through breakthroughs in insurtech, virtual access, immunotherapy, biologics, and precision oncology.
Leap Therapeutics' Phase 2 trial data show sirexatamab boosts response rates and survival in MSS colorectal cancer, with ongoing business development plans.
While sirexatamab combined with tislelizumab and chemotherapy showed some activity in biomarker-specific populations, the study failed to generate a clear positive signal on progression-free survival endpoints.
Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session.
Shares of FLJ Group Limited (NASDAQ: FLJ) shares jumped during Friday’s session after the company announced it entered into a definitive agreement to acquire Alpha Mind Technology. FLJ Group shares jumped 96.4% to $0.2123 on Friday.
